Critical Materials
PrivateA cyclically-impaired mineral-sands cash cow being repriced as the West's first integrated rare-earths refiner — own it for the 2027 Eneabba option, not the zircon, but only past the execution-and-funding cliff that ends in 2026.
Research
The verdict
A cyclically-impaired mineral-sands cash cow being repriced as the West's first integrated rare-earths refiner — own it for the 2027 Eneabba option, not the zircon, but only past the execution-and-funding cliff that ends in 2026.
Iluka Resources is the world's largest producer of zircon and a major producer of high-grade titanium-dioxide feedstocks (rutile and synthetic rutile, "SR"), now pivoting to become the first fully-integrated rare-earths refiner outside China. The business runs in three reportable buckets: Mineral Sands (the legacy cash engine), Rare Earths (the Eneabba refinery under construction), and Idle/Closed assets.
What it actually sells, and to whom:
Asset base:
Contract structure — the structurally important part. Iluka has shifted toward fixed-or-floor priced minimum-revenue contracts: for 2026 it has contracted ~110kt SR, 10kt rutile, 12kt HyTi and 100kt ilmenite with Western pigment customers underpinning minimum contracted revenue of ~A$240m. The first Eneabba rare-earths offtake (announced early 2026) with a global automaker is a four-year take-or-pay for ~1,200t of magnet REO (Nd/Pr/Dy/Tb) from 2028, with a US$155m minimum revenue floor (~US$172m at industry-forecast pricing, an ~11% uplift). That floor is the bankability anchor for a non-recourse refinery (Lens 11).
`` is empty — no compiled customer concentration. From the contract structure, concentration risk sits at the pigment-customer level (Western producers) for titanium feedstocks and at the single-automaker level for the first REO offtake.
Iluka is unusually vertically integrated for a miner — it mines, separates, and (from 2027) refines, which is the whole strategic point. Named chain, upstream → end customer:
Upstream inputs / suppliers:
Iluka (the converter): mine → Narngulu MSP (separation) → Capel SR kilns (ilmenite → synthetic rutile) → Eneabba refinery (monazite/concentrate → separated REOs, from 2027).
Downstream / end customers:
Chokepoints / single-source dependencies:
Names present, chain mapped — lens satisfied. (supply-chain.md commercial-layer file is missing; this is web-derived.)
Mineral sands — a cost/scale moat that is real but cyclical.
Bargaining power is currently weak on the sell side (pigment customers hold the cards in a glut — Iluka withdrew SR sales guidance because customers wouldn't commit) but the fixed-or-floor contracts claw some of it back by guaranteeing minimum volumes/revenue.
Rare earths — a policy-and-scarcity moat under construction. This is the durable-moat story:
Net moat verdict: the existing moat (zircon scale) is a depleting cyclical advantage; the prospective moat (ex-China integrated REO refining) is potentially far more durable but unproven and entirely execution-dependent. The bet is a moat transplant. (positioning.md/bottlenecks.md missing; web-derived.)
segments.csv is empty — no compiled segment rows. The following is web-sourced and should be treated as such.
| Segment | FY2025 | FY2024 | Trend & cause |
|---|---|---|---|
| Mineral Sands revenue | A$976m | A$1,129m | −13.5%. Driven by zircon price (−12.9% unit revenue) + pigment-demand collapse. |
| Underlying Mineral Sands EBITDA | A$300m | A$477m | −37%. Operating-leverage hit — revenue −13.5% but EBITDA −37%, the classic commodity de-gearing. |
| Underlying Group EBITDA | A$329m | A$499m | −34%. Group ≈ mineral sands + small other; rare earths is pre-revenue (capex, not EBITDA). |
| Rare Earths revenue | ~nil (pre-commissioning) | ~nil | Eneabba is in construction; first REO revenue ~2027–28. |
Within Z/R/SR (FY2025): zircon ≈ 65% of Z/R/SR revenue. Zircon sand sales 157kt + zircon-in-concentrate 111kt; zircon premium/standard price US$1,643/t (FY24: US$1,882/t). Blended Z/R/SR unit revenue A$1,913/t, −12.9% YoY. Total Z/R/SR production 559kt (above 495kt guidance; FY24 496kt) — Iluka out-produced into a falling-price market, which is part of the inventory problem (Lens 10).
Geography (FY2025, qualitative): China = largest zircon market, cautious/destocking; Europe firmer (opacifiers); global ceramic-tile production still contracting, led by China. No `` geographic revenue split available — n/a for a precise by-region table.
The headline: a statutory net loss of A$288m vs. A$231m profit in FY2024 — but the loss is manufactured by impairments; the cash business still made money.
Revenue & profit:
The A$566m exceptional breakdown:
Production & cost (the bright spot): Z/R/SR production 559kt vs 495kt guidance; unit cash cost US$1,054/t, below guidance — higher zircon volume diluted unit cost.
Balance-sheet flags (see Lens 10 for forensic detail): inventory balance ~A$1.1bn at 31 Dec 2025 after the NRV write-down — i.e. inventory still exceeds a full year of mineral-sands revenue. Net debt building fast: rare-earths-segment net debt A$584m + mineral-sands net debt A$473m at 31 Dec 2025 — combined ≈ A$1.06bn ``.
Guidance & outlook: management declined to give zircon volume/price guidance through much of 2025 (tariff uncertainty, customer reluctance) — a tone marker. FY2026 framed around lower cash outflow: 2026 cash requirements ~A$665m (down from 2025), 2026 cash costs of production ~A$420m (FY25 ~A$590m). Minimum contracted mineral-sands revenue ~A$240m for 2026.
Dividend: final 3cps fully franked; full-year 5cps (FY24 8cps) — a 37.5% cut, consistent with capital being redirected to Eneabba/Balranald.
Market reaction: brutal and repeated. Shares fell as much as −17% on the impairment/suspension news (worst session since March 2020), and −11–13% on other 2025/26 sessions. The market is trading the cycle and the capex cliff, not the rare-earths option — yet over the trailing 6 months ILU outperformed the All Ords by +19.25% as the REO narrative reasserted. High two-way volatility is the signature.
transcripts/ is empty — this is web-derived from the public call transcripts and presentations (HY25 20-Aug-2025, FY25 18-Feb-2026, Q4/full-year 29-Jan-2026, Macquarie Conf May-2025; all on iluka.com).
Tone arc across 2025–26:
What they started saying: rare-earths offtake, take-or-pay floors, government funding, "ex-China." What they stopped saying: zircon volume/price guidance (deliberately withheld), aggressive mineral-sands growth. Net: management has re-based expectations downward on mineral sands and re-anchored the equity story entirely on Eneabba — a tone shift from growth to survive-and-transform.
Iluka is a genuine two-business hybrid — mineral-sands (TiO₂-feedstock/zircon) peers AND rare-earths peers. Both sets shown. Multiples are `` with date or n/a. None fabricated.
| Company | Ticker | Mkt cap (USD) | EV/EBITDA | P/E | Div yield | Notes / provenance |
|---|---|---|---|---|---|---|
| Iluka Resources | ILU.AX | ~US$2.3bn `` | n/a (FY25 statutory loss) | n/m (loss) | ~0.4–0.7% | A$3.46bn mkt cap; net debt ~A$1.06bn |
| Mineral-sands / TiO₂ peers | ||||||
| Tronox | TROX | ~US$1.2–1.34bn | n/a (EV ~US$4.58bn) | n/a | n/a | TiO₂ pigment + feedstock integrated |
| Chemours | CC | ~US$3.3bn | ~12.6x | n/a | n/a | TiO₂ pigment; FL/GA mineral sands w/ monazite REE by-product |
| Kenmare Resources | KMR.L | ~US$0.22–0.23bn (£178m) | ~2.5x | ~5.5x trailing / ~9.6x fwd | n/a | Moma (Mozambique) ilmenite; deep-value optics |
| Rare-earths peers | ||||||
| Lynas Rare Earths | LYC.AX | ~US$12.8bn | ~83x (vs 10y median ~14x) | ~221x | n/a | Largest ex-China separated-REO producer; richly valued |
| MP Materials | MP | ~US$10.8bn | n/a (LTM loss) | n/m (loss) | n/a | Mountain Pass; mine+separation+magnets; US gov-backed |
| Energy Fuels | UUUU | ~US$4.1bn | n/a | n/a | n/a | Uranium + REO; first US heavy-REO production 2026 |
5-yr avg ROE for the peer set: n/a (would be fabrication to assert; multiple peers are loss-making, making a clean 5-yr ROE meaningless without the underlying series).
Read: the rare-earths peers (Lynas ~83x EV/EBITDA, MP ~US$10.8bn on US$348m revenue) trade on strategic-scarcity multiples that have nothing to do with current earnings — they are repriced as sovereign-supply-chain assets. The mineral-sands peers (Chemours ~12.6x, Kenmare ~2.5x, Tronox) trade on cyclical-industrial multiples. Iluka sits awkwardly between: priced today closer to a cyclical mineral-sands miner (~A$3.46bn for a business that did A$329m underlying EBITDA), with a free rare-earths option the market only part-credits. If Eneabba delivers, the re-rate vector is toward the Lynas/MP cohort; if it stumbles, the floor is the mineral-sands cohort. That asymmetry is the entire investment case.
What actually moves ILU >5%, from the visible record:
Pattern verdict: historically a commodity-price/earnings stock (zircon + TiO₂). It is transitioning into a policy/strategic-narrative stock (rare earths). 2025–26 is the awkward overlap where bad mineral-sands prints and good rare-earths headlines fight — hence the violent two-way volatility (52-wk range ~A$3.41–9.48 ).
CEO: Tom (Thomas) O'Leary — MD/CEO since September 2016 (~9.5-yr tenure). Background: 30+ years in executive management, business development and investment banking; previously MD of Wesfarmers Chemicals, Energy & Fertilisers.
(1) Track record. O'Leary has run Iluka through a full mineral-sands cycle. The defining capital-allocation act of his tenure is the strategic pivot into rare earths — securing the Eneabba refinery and ~A$1.65bn of government funding, arguably positioning Iluka for a structural re-rate. He also oversaw the 2022 demerger of Sierra Rutile (separating the African asset) and Deterra Royalties (the iron-ore royalty spin-out, 2020) — both shareholder-value-conscious moves. Counter-mark: the FY2025 A$566m impairment and the Cataby reserve cut happened on his watch — capital was sunk into SW-WA assets now impaired.
(2) Tenure & skin in the game — a flag. O'Leary directly owns ~0.35% (~A$11.3m). More pointed: he conducted a ~A$5.5m share sale plus trust transfers, with no recent insider buying from CEO or Chair — characterised by at least one analyst as "not skin in the game; a pattern of sales and inaction". insider-transactions.csv is absent — cannot independently verify the full insider series; treat as ``. For a 9.5-year CEO selling into a transformation he's asking shareholders to fund, the optics are poor (Lens 13 weighs this).
(3) Capital-allocation history. Mixed-to-good historically (Deterra/Sierra Rutile demergers crystallised value; disciplined dividends in the up-cycle). Now in heavy-reinvest mode: dividend cut 8→5cps, capital funnelled into Eneabba + Balranald. The bet is enormous relative to the A$3.46bn market cap — A$1.65bn government facility + Iluka equity. ROE/ROIC has gone negative in FY2025 on the impairment; on a normalised basis the historical returns were respectable. n/a for a clean multi-year ROIC series.
(4) Red flags. The CEO share-sale-without-buying pattern (above). No related-party or governance scandal surfaced. The 2022 shareholder class action was dismissed in full (Lens 10) — a clean disclosure record under litigation test.
(5) Founder vs professional manager. O'Leary is a professional manager / financier-operator (ex-IB, ex-Wesfarmers), not a founder. For a capital-intensive, government-financed transformation requiring project-execution discipline and balance-sheet stewardship, a financier-operator is arguably the right archetype — but the lack of personal buying means his alignment is via comp, not conviction.
Forensic-analyst lens. Web-only — no filings on the shelf to tie to. Figures labeled.
Income statement. The A$288m statutory loss is impairment-driven, not operational — the underlying business generated A$329m group EBITDA. Healthy that the charge is flagged as a discrete exceptional; unhealthy that it signals the SW-WA asset base (Cataby/SR kilns) was carried too high and is now reserve-cut 35%. Watch whether further impairments follow if zircon stays weak.
Balance sheet — the standout forensic flag: inventory. Inventory ~A$1.1bn at 31 Dec 2025 after a A$215m NRV write-down. That is inventory > a full year of mineral-sands revenue (A$976m) — an extreme build. Iluka out-produced guidance (559kt vs 495kt) into a falling-price, weak-demand market, accumulating finished/WIP stock. Bull read: a "zircon bank" — inventory monetisable when prices recover, deferred not destroyed value. Bear read: classic inventory outrunning sales, NRV risk if prices fall further, and cash trapped in working capital exactly when the company is funding two megaprojects. This is the single most important forensic line in the dossier — cash conversion is being strangled by inventory.
Net debt trajectory. Combined segment net debt ≈ A$1.06bn (RE A$584m + MS A$473m) at 31 Dec 2025 ``, up from ~A$502m at June 2025. The EFA government loan is non-recourse (ring-fenced to the RE project) — a genuine structural protection: if Eneabba fails, the government loan does not sink the parent. But the mineral-sands segment net debt + the MOFA (A$800m facility, A$500m drawn, expires May 2029) is recourse, and that is the balance sheet that must survive the trough. Reported "net debt ~1.0x EBITDA" looks benign but rests on a trough EBITDA and excludes the working-capital drag.
Cash flow vs earnings. FCF not cleanly sourced (n/a for an exact FY25 FCF figure), but the directional read is clear: heavy capex (Eneabba/Balranald) + inventory build = negative free cash flow, funded by debt draws (MOFA + EFA). 2026 cash requirements ~A$665m against a business doing ~A$300–330m EBITDA means continued external funding reliance through 2026.
SBC / non-GAAP flattering. No evidence Iluka leans on SBC to flatter non-GAAP (it reports "underlying" cleanly stripping the A$566m exceptional). Not a flagged issue.
Regulatory findings (required sub-section):
regulatory/regulatory-findings.md (fetched 2026-06-30) confirms Iluka has no CIK and is not an SEC filer — zero EDGAR enforcement possible ``. Not applicable to an ASX-only issuer.n/a for a verbatim quote.Build basis (all inputs → outputs; arithmetic shown). Shares outstanding ≈ ~430m ``. Caveat: market-cap-implied count (494m) conflicts with historical ~430m; I flag the conflict rather than pick silently. EPS below uses 430m; if 494m the per-share figures scale down ~13%.
FY2025 actuals: Mineral Sands revenue A$976m, Group underlying EBITDA A$329m, statutory net loss A$288m (impairment-driven), Z/R/SR 559kt, blended unit revenue A$1,913/t.
The honest answer: FY2026–27 EPS is dominated by (a) where zircon/TiO₂ prices land, and (b) Eneabba commissioning timing/cost — both genuinely uncertain. Rather than fabricate precision, three scenarios:
| Path | FY2026 | FY2027 | FY2028 | Drivers |
|---|---|---|---|---|
| Bear | small loss / breakeven | breakeven | modest profit | Zircon stays ~US$1,400/t or lower; pigment demand flat; Eneabba slips into 2028 / cost overrun; inventory NRV risk. Underlying EBITDA ~A$250–300m, eaten by D&A + interest on rising debt. `` |
| Base | ~A$0.10–0.25 EPS | ~A$0.30–0.50 EPS | ~A$0.50–0.80 EPS | Zircon stabilises ~US$1,400–1,600; cost-out delivers (cash costs A$420m vs A$590m); Eneabba commissions 2027, first REO revenue + US$155m+ offtake floor from 2028; inventory partially monetised. `` |
| Bull | ~A$0.25+ | ~A$0.60+ | ~A$1.00+ | Zircon recovers toward US$1,800+; Eneabba on-time/on-budget and ramps fast with strong NdPr/Dy/Tb pricing on persistent China controls; merchant-refining (Lindian + 3rd-party) adds volume; re-rate to strategic multiple. `` |
n/a for a precise sell-side consensus EPS line (the search surfaced price targets — avg ~A$7.66–8.07, range A$5.25–9.50 — but not a clean consensus EPS series; I will not fabricate one).
Brier forecast: skipped — per SKILL --watchlist rule, do not run forecast.ts create in the breadth loop. The base case is not yet a committed call. The natural binary to track later: "Eneabba refinery achieves first separated-REO production by 31 Dec 2027" (p ≈ 0.55 `` — management now guides mid-2027 commissioning at >50% complete and within budget, which nudges the base case up slightly, but megaproject base rates still argue for slippage risk).
Bull case. Iluka is a cyclically-depressed mineral-sands cash cow stapled to the most strategically valuable rare-earths option on the ASX. The zircon franchise (Jacinth-Ambrosia, world's largest) is trough-earning, not broken — a price recovery flows straight to EBITDA given cost leadership, and the ~A$1.1bn inventory is a "zircon bank" that monetises on recovery. Meanwhile Eneabba makes Iluka one of very few ex-China integrated light+heavy REO refiners, ~A$1.65bn government-funded (mostly non-recourse — downside ring-fenced), with a first take-or-pay automaker offtake (US$155m floor) proving commercial bankability. China's heavy-REO export licensing (never lifted) is a structural tailwind that only grows. If Eneabba commissions in 2027 and re-rates ILU toward the Lynas/MP strategic-multiple cohort, the upside is multiples of today's A$3.46bn. Capital intensity peaks in 2026 then falls (cash needs A$665m, costs A$420m) — the cash-flow inflection is visible. Macquarie's top mineral-sands pick with a free rare-earths call option.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): Most likely failure mode — Eneabba commissioning slips to late-2028 with a A$200–400m overrun, while zircon stays ~US$1,300 and pigment demand never recovers. Iluka draws the full MOFA, cuts the dividend to zero, raises equity at a depressed price to plug the recourse balance sheet, and the "strategic re-rate" never arrives because China lets REO prices sag. The stock re-tests the A$3.41 low.
Are multiples too high? On trailing numbers Iluka screens as a loss-maker (no meaningful P/E); on EV/EBITDA it's ~mid-single-digits on trough EBITDA — not demanding for the mineral-sands business alone. The rare-earths option is only partly in the price. Multiples are not the risk — execution is.
Contrarian view (what the market refuses to see): The market is anchored on the zircon downturn and the capex cliff and treating Eneabba as a cost/risk. The contrarian read: Eneabba is a sovereign-strategic call option the West needs to work — and in a world re-pricing supply-chain security, a non-recourse-funded, government-sponsored, ex-China integrated heavy-REO refiner is worth far more as a strategic asset than a DCF on first-offtake economics suggests. The asymmetry (mineral-sands floor + strategic-REO upside) is being mis-weighted because 2026 is the ugly bridge year.
Dismantling the bull case.
A self-help margin re-rating priced as a doomed smelter — the $0 TC/RC tape masks that Aurubis already earns more from downstream premiums, recycling and a finished $1.7B capex cycle than from the concentrate spread the bears fixate on; watching, not yet a buy, because the metal-price tailwind that lifted FY25/26 guidance twice is the same lever that breaks on a copper pullback.
A 38-year, $1.7B-NPV NdPr asset that the equity market is pricing as a serial dilution machine — the call is on financing-close + China's price floor, not the ore body. WATCHING into FID-completion; the project is fundable, the share count is the bear case.
A best-in-class, Luksic-controlled Chilean copper pure-play priced for the 30% volume ramp it has not yet delivered — own the asset, not this multiple; the entry is a copper-price dip or a Centinela-2 commissioning wobble, not 14x EV/EBITDA on a name that just missed guidance again.